EGFR and pancreatic neoplasm: Metastatic human pancreatic cancer cells (the SW1990 line) that are resistant to the EGFR-targeting tyrosine kinase inhibitor drugs (TKI) erlotinib and gefitinib were treated with 1,3,4-O-Bu3ManNAc, a “metabolic glycoengineering” drug candidate that increased sialylation by ∼12-fold.